Department of Pathology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India.
Department of Surgery, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India.
J Cancer Res Ther. 2021 Jul-Sep;17(4):887-892. doi: 10.4103/jcrt.JCRT_619_18.
CD10 plays a role in signal transduction pathway and regulation of cell growth apoptosis, and therefore, it has been evaluated in different malignancies. The present study was conducted to study the immunoexpression of CD10 in urothelial carcinoma and to correlate it with histological grade, pathological stage, and survival of patients.
The study included 51 cases of urothelial carcinoma diagnosed on histopathology along with 50 controls having nonneoplastic urothelium. All the cases and controls were subjected to CD10 immunostaining. The CD10 expression was compared between the cases and controls and was also correlated with histological grade, pathological stage, histomorphological features, and 1-year survival.
The study included 78.4% of high-grade urothelial carcinoma (HGUC) and 21.6% of low-grade urothelial carcinoma. The positive score of CD10 expression was observed in 68.6% of cases, while 96% of controls observed negative immunostaining. About 90.9% of low-grade carcinoma observed score 0, while 83.7% of high grade observed positive score of 1 and 2. Although there was statistical significant difference between CD 10 score and stage of tumor, its expression did not correlate with 1-year survival of cases.
CD10 expression increases with the grade of tumor and thus may be helpful in differentiating low grade from HGUC. Its expression also increases with stage and poor prognostic factors suggesting its possible role in pathogenesis and progression of urothelial carcinoma. CD 10 may be further analyzed for molecular targeted therapy against urothelial carcinoma.
CD10 在信号转导途径和细胞生长凋亡的调节中起作用，因此已在不同的恶性肿瘤中进行了评估。本研究旨在研究 CD10 在尿路上皮癌中的免疫表达，并将其与患者的组织学分级、病理分期和生存相关联。
该研究包括 51 例经组织病理学诊断的尿路上皮癌病例，以及 50 例具有非肿瘤性尿路上皮的对照病例。所有病例和对照均进行 CD10 免疫染色。比较病例和对照之间的 CD10 表达，并与组织学分级、病理分期、组织形态学特征和 1 年生存率相关联。
该研究包括 78.4%的高级别尿路上皮癌（HGUC）和 21.6%的低级别尿路上皮癌。CD10 表达阳性评分在 68.6%的病例中观察到，而 96%的对照病例观察到阴性免疫染色。约 90.9%的低级别癌观察到评分 0，而 83.7%的高级别癌观察到评分 1 和 2。虽然 CD10 评分与肿瘤分期之间存在统计学显著差异，但它的表达与病例的 1 年生存率无关。
CD10 的表达随着肿瘤的分级而增加，因此可能有助于区分低级别和 HGUC。它的表达也随着分期和不良预后因素的增加而增加，提示其在尿路上皮癌的发病机制和进展中可能发挥作用。CD10 可能进一步分析用于针对尿路上皮癌的分子靶向治疗。
